# A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

> **NCT07101614** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 125 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** JS004 in combination with toripalimab and chemotherapy
- **DRUG:** Toripalimab and chemotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07101614
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101614, "A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07101614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*